Celerion's Hybrid Phase I/ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network.
Based on knowledge gained from conducting more than 40 TQT studies and 100 SAD/MAD studies with intensive ECG monitoring, Celerion has developed a Hybrid Phase I/ ECG Core lab with much smaller overhead compared to traditional ECG Core labs supporting global clinical trials. Further efficiencies are generated by fully integrating the core lab and clinic functions enabling the Sponsor to work with one entity, thereby minimizing the requirements to manage two functions in areas such as contracts, audits and study initiation.
The highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings and effectively identifies the small number of ECG recordings that require cardiologist review. By minimizing cardiologist review, integrating functions and decreasing overhead, Celerion is able to offer significant cost and time savings to clients for the execution of Thorough QT studies and ECG assessment in SAD and MAD programs.
The introduction of the Hybrid ECG Core lab clearly establishes Celerion as a world leader in innovative early cardiac services. Please contact us for additional information or to speak to a representative.